Among the 18 patients, 16 patients displayed low levels of IL6 during CRS, and 2 patients displayed moderate levels of IL6 with very low levels of IFNG during only grade 1 CRS, therefore not requiring Tocilizumab for blocking IL6 signaling. Here, IL6 is linked to congenital rubella syndrome.